Navigation Links
'Designer' sedative may provide new alternative for colonoscopy
Date:10/28/2013

San Francisco, CA. (October 28, 2013) Developed using molecular-level techniques, the "designer" sedative drug remimazolam provides a promising new alternative for sedation in patients undergoing colonoscopy, reports a study in the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

"Remimazolam has the attributes of a sedative drug, with success rates comparable with recent studies of other drugs," according to the new research, led by Dr Mark T. Worthington of Johns Hopkins Hospital, Baltimore.

Remimazolam Shows Fast Onset of Sedation and Quick Recovery

The researchers evaluated the use of remimazolam, a new benzodiazepine-type sedative drug, for sedation in patients undergoing colonoscopy. As described in a recent article in Anesthesia & Analgesia, remimazolam is an example of new anesthetic and sedative drugs being developed with the use of molecular-level techniques. Remimazolam was specifically designed to have a faster onset, more predictable effects, and shorter recovery time compared to currently available sedatives.

In the "dose-finding" study, 44 volunteers received one of three different doses of remimazolam. Across dose groups, remimazolam successfully provided an adequate level of sedation for colonoscopy in three-fourths of patients.

Remimazolam achieved adequate sedation less than one minute after drug administration. Afterwards, all subjects "rapidly recovered to fully alert"the median recovery time was less than 10 minutes.

A few subjects did not achieve adequate sedation or had minor adverse events, such as a drop in blood pressure. There were no serious or unexpected adverse events, however.

Further experiments showed that the sedative effect of remimazolam could be rapidly reversed using flumazenilan approved medication that blocks the benzodiazepine receptor. Patients regained full alertness within one minute after flumazenil injection.

Colonoscopy is commonly performed as a screening test for colorectal cancer. For this and other brief medical procedures, some form of sedative is needed to minimize patient discomfort and optimize performance of the procedure. The ideal sedative would have a fast onset and good quality of sedation, along with rapid recovery time.

Conventional benzodiazepines provide effective sedation but relatively long recovery timespatients may not return to their normal level of alertness and functioning for several hours after the procedure. The new study is the first to compare the effects of various doses of remimazolam as sedative for colonoscopy.

The new results show "very encouraging" success rates with remimazolam, Dr Worthington and coauthors write. With its fast onset and quick recovery timeincluding the ability to reverse sedation almost immediately, if neededremimazolam could be a valuable new sedative option for use in colonoscopy and other brief medical procedures. However, the researchers note that further studies will be needed to "refine the optimal dosing regimen" before remimazolam goes into widespread clinical use.

Read the article in Anesthesia & Analgesia


'/>"/>

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
2. NJIT designer creates an ergonomic chair for musicians
3. Circadian clock research may enable designer plants, and cancer and diabetes treatments
4. Websites Touting Designer Vagina Surgeries Often Inaccurate, Study Finds
5. Chicago Hat Designer Tonya Gross Selected by Online Retailer Zappos.com for 2013 Emerging Designer Program
6. Author/Designer Perla Lichi Links Her Coffee Table Book "Palaces" With Upcoming On-Line Training Course
7. Contemporary Heaven Launches High-End Traditional and Modern Designer Pendant Lights
8. Dr. Daniel Strader of Dallas Designer Smiles Receives Top Reviews as Local Dallas, TX Dentist for Biological Dentistry
9. Fashion Designer Jenny Rose Creates Arabic Swimwear
10. Renowned Jewelry Designer Kendra Scott Hosted a Successful ‘Kendra Gives Back’ Party Benefitting Colleen’s Dream Foundation in Scottsdale, AZ
11. Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: